Roche immunotherapy Tecentriq has won EU approval for treating advanced lung and bladder cancer, Reuters Health reports the Swiss drugmaker said. The European Commission approved Tecentriq, also known as atezolizumab, as a monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) after patients have been treated with chemotherapy.
The report says the EC also approved the drug as a monotherapy for treating people with locally advanced or metastatic urothelial carcinoma (mUC) who have been treated with a platinum-containing chemotherapy or who are considered ineligible for cisplatin chemotherapy.
“We are delighted that the European Commission has approved Tecentriq, the first anti-PD-L1 cancer immunotherapy approved in the EU, as a monotherapy in both advanced bladder and advanced lung cancer,” Roche chief medical officer Sandra Horning said.
The report said the therapy is already approved in the US and several other countries for people with metastatic NSCLC, people with mUC who are not eligible for cisplatin chemotherapy, or those whose disease progresses during or after platinum-containing therapy.Reuters Health report